Menu Search
Equities

OptiBiotix Health PLC

OB3:FRA

OptiBiotix Health PLC

Actions
  • Price (EUR)0.145
  • Today's Change-0.002 / -1.36%
  • Shares traded10.00k
  • 1 Year change-53.23%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 08:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.

  • Revenue in GBP (TTM)569.00k
  • Net income in GBP-2.98m
  • Incorporated2006
  • Employees5.00
  • Location
    OptiBiotix Health PLCInnovation CentreInnovation Way, HeslingtonHESLINGTON Y010 5DGUnited KingdomGBR
  • Phone+44 207 933 8780
  • Websitehttp://www.optibiotix.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.